Sort
30,917 grants matching “tumor microenvironment”
Image Biomarker Development for TreatmentEfficacy of Prostate Cancer to the Bone
$543,962Brian D. Ross · University Of Michigan At Ann Arbor · R01 · FY2010 · CA
NR4A1 Antagonists Inhibit Colorectal Cancer Growth and Enhance Immune Surveillance
$543,717Stephen H Safe · Texas A&M University · R01 · FY2024 · CA
Novel Methods of Chemo-sensitizing Low-proliferative Disseminated Tumor Cells in Triple Negative Breast Cancer
$543,700David D Tran · University Of Florida · R01 · FY2021 · CA
Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cells
$543,694Johannes Zakrzewski · Hackensack University Medical Center · R37 · FY2023 · CA
New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma
$543,634John L. Cleveland · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2022 · CA
New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma
$543,634John L. Cleveland · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2023 · CA
The role of inflammation in the regulation of immune response in acute myeloid leukemia
$543,631Iannis Aifantis · New York University School Of Medicine · R01 · FY2024 · CA
Protein Structure, Stability, and Amyloid Formation
$543,630Ruth Nussinov · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
PROJECT 1: From Neurofibroma to MPNST: Models, Biology and Translation to Clinic
$543,627David W. Clapp · Indiana University Indianapolis · U54 · FY2023 · CA
Mechanism of microbiota-mediated potentiation of checkpoint blockade efficacy in lung cancer
$543,560Dan R Littman · New York University School Of Medicine · R01 · FY2024 · CA
Novel therapeutics dual targeting intracrine androgen synthesis and AR for advanced prostate cancer
$543,427Allen C Gao · University Of California At Davis · R01 · FY2022 · CA
The Core of the Computational Biology
$543,259Stephen Tc Wong · Methodist Hospital Research Institute · U54 · FY2010 · CA
Immune epigenetic biomarkers of survival in glioma epidemiology
$543,240John K. Wiencke · University Of California, San Francisco · R01 · FY2021 · CA
Project 3: Adaptive immunity to MCPyV in Merkel cell carcinoma
$543,162David M Koelle · University Of Washington · P01 · FY2020 · CA
Engineered ECM platforms to analyze progression in high grade serous ovarian cancer
$543,106Pamela K Kreeger · University Of Wisconsin-Madison · R01 · FY2022 · CA
3-D spatial approach to discover genomic effectors of immunosuppression during malignant transformation
$543,064Joseph F Costello · University Of California, San Francisco · R01 · FY2024 · CA
Understanding the Impact of Microscale and Nanoscale Heterogeneity and Resistance
$543,061Joe W. Gray · Oregon Health & Science University · U54 · FY2019 · CA
The Role of the Y Chromosome in Bladder Tumor Development, Growth And Progression
$543,058Dan Theodorescu · Cedars-Sinai Medical Center · P01 · FY2023 · CA
The Role of the Y Chromosome in Bladder Tumor Development, Growth And Progression
$543,058Dan Theodorescu · Cedars-Sinai Medical Center · P01 · FY2025 · CA
Non-coding RNA regulation of Myeloid Cells
$543,051Jorge Henao-Mejia · University Of Pennsylvania · R01 · FY2025 · CA
Immune Therapy for Brain Metastasis
$542,905Lucia Beatrice Jilaveanu · Yale University · R01 · FY2024 · CA
Armed nanobodies as anti-infectives and anti-tumor agents
$542,900Hao Wu · Boston Children'S Hospital · R01 · FY2024 · AI
Armed nanobodies as anti-infectives and anti-tumor agents
$542,900Hao Wu · Boston Children'S Hospital · R01 · FY2025 · AI
Elucidating the Role of Cancer-Associated FGL1 in Tumor Immunity and Developing FGL1-Guided Anti-LAG-3 Cancer Immunotherapy
$542,889Jun Wang · New York University School Of Medicine · R37 · FY2024 · CA
Optimizing singlet oxygen dosimetry for photodynamic therapy (PDT)
$542,726Timothy C Zhu · University Of Pennsylvania · R01 · FY2024 · EB